CRB-913 in Obesity
CRB-913 demonstrated a favorable safety profile with mean weight loss of up to 5% at 12 weeks with no plateau observed. These data support CRB-913’s potential to establish a new class of non-incretin obesity medicines. The data was selected for a late-breaking presentation at ObesityWeek® 2026
CRB-913 is a once-daily, highly peripherally restricted oral CB1 inverse agonist designed as a potential non-incretin approach to weight loss and long-term weight management.
Explore the Canyon-1 data including the press release, corporate presentation, KOL webcast, media coverage and upcoming scientific conferences.
Upcoming
Presentations and Events
CRB-913 at Obesity Week 2026
CANYON-1 data have been selected for a late-breaking presentation at ObesityWeek 2026, taking place November 14–17 in Washington, DC.
Featured Coverage and Interviews
Explore recent coverage and conversations about CANYON-1, CRB-913 and the evolving treatment landscape in obesity.
Featured Article
Trial breakthrough for weight-loss drug with fewer side effects
Financial Times
Ahead of CANYON-1: CRB-913 and its potential in obesity
Ahead of the CANYON-1 topline data readout, Corbus CEO Yuval Cohen discussed CRB-913 and its potential in obesity on the Molecules and Minerals podcast.